Abstract
EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.
| Original language | English |
|---|---|
| Pages (from-to) | 105-108 |
| Number of pages | 4 |
| Journal | Gynecologic Oncology |
| Volume | 56 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 7 1995 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Oncology
Cite this
A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. / Hartenbach, Ellen M.; Saltzman, Andrew K.; Carter, Jonathan R.; Twiggs, Leo B.
In: Gynecologic Oncology, Vol. 56, No. 1, 07.02.1995, p. 105-108.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease
AU - Hartenbach, Ellen M.
AU - Saltzman, Andrew K.
AU - Carter, Jonathan R.
AU - Twiggs, Leo B.
PY - 1995/2/7
Y1 - 1995/2/7
N2 - EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.
AB - EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.
UR - http://www.scopus.com/inward/record.url?scp=0028917983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028917983&partnerID=8YFLogxK
U2 - 10.1006/gyno.1995.1019
DO - 10.1006/gyno.1995.1019
M3 - Article
C2 - 7529741
AN - SCOPUS:0028917983
VL - 56
SP - 105
EP - 108
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -